AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tempest Therapeutics, Inc. Director's Dealing 2018

Dec 12, 2018

34632_dirs_2018-12-11_b7fe5b14-1dd2-4777-a30c-a56673072004.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2018-12-07

Reporting Person: Gallagher Carol Giltner (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-12-07	Common Stock	A	8249	—	Acquired	8249	Direct
2018-12-07	Common Stock	A	23684	—	Acquired	23684	Indirect

Footnotes

F1: Received in exchange for 110,887 shares of Millendo Therapeutics, Inc. common stock in connection with merger of Millendo Therapeutics, Inc. into the Issuer.

F2: Received in exchange for 318,335 shares of Millendo Therapeutics, Inc. common stock in connection with merger of Millendo Therapeutics, Inc. into the Issuer.